Pump.fun (PUMP) price recovered to around $0.005839 after dipping to $0.005383, bringing the key $0.006 resistance level back into focus. Technical indicators like the Aroon and Supertrend remain bullish, and analysts have identified a bullish flag and a cup-and-handle pattern suggesting potential upside if PUMP breaks above $0.006. The next target could be near $0.00740, about 26.7% above the current price, but failure to hold above $0.00545 could lead to a pullback. Meanwhile, liquidation clusters near $0.00587 and $0.006 indicate resistance zones. Ongoing buybacks totaling over $23 million in the past month support price strength amid a cautious US rate environment.
Pump.fun price prediction is the subject, with Pluang market data as context. As of Oct 02, 2026 00:23 WIB, among 50 major cryptocurrencies on Pluang, 14 rose and 35 fell. Notable movers include VET at Rp156 with a 3.16% decline and a typical hold time of 147 days, ATOM at Rp30.952 down 2.74% with 60 days typical hold, and GRT at Rp515 down 2.32% with a 98-day hold. The most notable figure is the 56% buy order activity for VET.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
